Pharmacists Role in Enhancing Diabetes Management During Pregnancy: A Discussion on Continuous Glucose Monitors (CGMs)
In recent years, advancements in diabetes technology, particularly the emergence of continuous glucose monitors (CGMs), have revolutionized disease management.
Notably, these innovative devices have showcased promising benefits for pregnant individuals, mitigating the risks associated with diabetes during pregnancy for both mother and baby.
Drug Topics engaged in a comprehensive conversation with Kevin Malloy, PharmD, BCPS, to delve into the realm of diabetes technology, specifically focusing on how it aids pregnant individuals in managing their condition.
Tip: Please fill out the form if you or a friend would like more information on CGM devices.
Malloy shared insights on the utility of CGMs during pregnancy and shed light on how pharmacists play a crucial role in guiding pregnant individuals in using these devices effectively.
Evolution of Diabetes Technology and Its Impact on Pregnancy
The conversation commenced by highlighting the substantial advancements witnessed in diabetes technology.
Malloy emphasized the groundbreaking approval of continuous glucose monitors specifically designed for pregnancy, citing notable examples such as the Dexcom G7 and the updated sensors for Freestyle Libre 2 and Freestyle Libre 3.
Reflecting on the extensive data collection spanning two decades, Malloy underscored the challenges of obtaining regulatory approval for these devices in pregnancy, emphasizing the significance of these approvals in advancing maternal and fetal health.
Must Read CGMs in noncritical care hospitals optimizes glycemic control
Balancing Caution and Advancements: Leveraging CGMs in Pregnancy
Malloy addressed the cautious approach in leveraging CGMs in a vulnerable population, acknowledging the scarcity of data and regulatory approval.
However, he emphasized the potential of CGMs as minimally invasive devices that could pave the way for more advanced interventions, like insulin pumps automatically adjusting insulin delivery.
He stressed the importance of not withholding these technologies due to limited reported evidence, especially in a population where optimal glycemic control remains a challenge.
Also, read about GLP-1 Drugs and Colorectal Cancer Risk Reduction
Maximizing Benefits: Pharmacists’ Role in CGM Use for Pregnant Individuals
The discussion further delved into the utility of CGMs during pregnancy. Drawing from trials, including the pivotal Concept Trial of 2017, Malloy highlighted the significant improvements in maternal glycemic outcomes and maternal-neonatal health with CGM use.
He emphasized ongoing trials exploring CGM use in preexisting type 1, type 2, and gestational diabetes, aiming to enhance glycemic control and obstetric outcomes.
Read Guide about Wegovy Dosage Guide: The Best Way For Weight Loss
Pharmacists, Malloy emphasized, play a vital role in guiding pregnant individuals in effectively utilizing CGMs to monitor their condition, thereby contributing to improved maternal and fetal health.
The discourse concluded by emphasizing the need to gather data on newer devices to further enhance their effectiveness and routine use, building upon the positive outcomes observed in previous trials.
